In April 2024, biotechnology company Vertex Pharmaceuticals ("Vertex") shared via news release that it was advancing its therapeutic candidate inaxaplin (VX-147) into the Phase 3 portion of a Phase 2/3…
On April 30, 2024, the American Kidney Fund (AKF) will be organizing the first annual APOL1-mediated kidney disease (AMKD) Awareness Day. This awareness day will be a time to…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
